Vidac Pharma Holding
Latest round
- Series A
Last raised
- Jun 2016
Total raised
- $9M
Investors
- 1
About Vidac Pharma Holding
Vidac Pharma Holding Plc, founded in 2011, operates from London, UK. The company specializes in pioneering biopharmaceutical innovations, particularly in oncology and dermatology. It has successfully completed 2 deals to date, with the most recent deal occurring on November 7, 2024.Vidac Pharma specializes in pioneering biopharmaceutical products focusing on oncology and dermatology. The company’s primary product offering is VDA-1102, an innovative drug candidate aimed at treating advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL). Utilizing Vidac’s proprietary Novel Chemical Entities (VDA-NCEs), these treatments work by reversing the Warburg effect, thereby inhibiting tumor hyper-growth and reactivating the immune response to combat cancer proliferation. Vidac Pharma targets healthcare providers and institutions as its primary customer base, ensuring that their advanced therapies reach patients suffering from these oncologic and dermatologic conditions.Vidac Pharma's revenue model is centered around partnerships with healthcare providers and institutions to distribute its products, particularly VDA-1102. The company engages in B2B transactions, where healthcare providers purchase the drug candidates for use in clinical settings, focusing on hospitals and specialized treatment centers. This structure may include agreements for exclusive distribution rights in certain territories, enabling tailored pricing strategies based on market demand and competitor positioning. Revenue is generated through direct sales transactions, potentially structured around contractual agreements that specify delivery schedules and quantities. The company is focused on launching new products, including VDA-1102, which is poised to significantly impact the oncology market. Additionally, Vidac aims to expand its reach into new geographic regions, particularly targeting North America and Europe, as it seeks to meet the increasing demand for advanced cancer therapies. This strategic focus is expected to enhance its market presence and drive future growth.
Who invested in Vidac Pharma Holding
1 investor across 1 round
See all investors in Vidac Pharma Holding
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 29, 2016
Amount
$9M
Investors
Questions about Vidac Pharma Holding
Who invested in Vidac Pharma Holding?
Vidac Pharma Holding has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vidac Pharma Holding raised?
Vidac Pharma Holding has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Vidac Pharma Holding last raise money?
Vidac Pharma Holding's most recent round on record is a Series A, in Jun 2016.
What does Vidac Pharma Holding do?
Vidac Pharma Holding Plc, founded in 2011, operates from London, UK.
Where is Vidac Pharma Holding headquartered?
Vidac Pharma Holding is headquartered in London, UK.
Which VCs invest in companies like Vidac Pharma Holding?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Vidac Pharma Holding's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Vidac Pharma Holding? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.